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Hidradenitis suppurativa (HS; or acne inversa) is a scar-
ring and frequently persistent inflammatory disorder of 
the terminal hair follicles of apocrine gland-bearing skin 
in adults. Treatments include local or systemic antibiotics, 
hormones, retinoids and systemic immunosuppressive 
agents (1), although on evaluation these have been shown 
to have only limited or temporary effect. In refractory 
cases, surgery is necessary, and should be radical and 
performed as early as possible (2, 3). 
It is essential to establish a registry of HS in order 
to address the following important issues: to assess 
the safety and effectiveness of different treatments; to 
identify which specific patient subgroups have the best 
risk/benefit ratio for a given treatment; and to create 
benchmark data for quality assurance of the medical 
service. This Letter to the Editor presents the Scandi-
navian Registry for HS, HISREG.
METHodS
In brief, the cases included in HISREG comprise individuals of 
any age with a diagnosis of, and/or ongoing treatment for, HS. 
Diagnosis of HS is made clinically using established criteria 
and terminology according to the First Hidradenitis Suppurativa 
Research Meeting in Dessau, Germany in 2006, as reviewed 
previously (1). Only subjects with a clinically convincing di-
agnosis are included. If the diagnosis is uncertain, additional 
previous medical records are requested in order to determine 
an accurate diagnosis. 
Three separate groups are involved in the production of the 
clinical database, as follows:
1. clinicians, who define the scope and the content of the 
database;
2. technicians, who enter all variables into the software, test 
and make necessary ongoing adjustments; 
3. administrators, who keep the process on track and provide 
support regarding legislative framework.
Written informed consent is obtained from the study partici-
pants, or their parents for individuals younger than 18 years, 
prior to inclusion. The work is performed according to the 
principles of the Declaration of Helsinki.
All relevant information on HS and related disorders was 
gathered from the literature and from the clinical experience of 
the authors in order to create a long primary list of items, which 
was subsequently reduced to as few items as possible after a series 
of discussions. The steering committee of HISREG. A selection 
of variables is shown in Fig. 1. The intention in excluding some 
data that was perhaps relevant to the disease was to ensure that 
the primary end-points would not be hidden by a cluster of data 
and thus probably not entered into the database at all. If too 
many items were included the project would be less reliable. For 
primary end-points: the Dermatology Life Quality Index (DLQI) 
(4), Sartorius score (5, 6) and classification according to Hurley 
(7) were chosen. Cases are prospectively followed. Data on 
demographics, social, educational, economic, and health status, 
quality of life, family history of HS, co-morbidities, potentially 
predisposing trigger factors surrounding onset and new attacks, 
previous and ongoing medication, characterization of attacks, and 
severity of symptoms are obtained. The database is populated 
with data: (i) from the patient’s point of view; and (ii) from the 
doctor’s own record simultaneously for each time-point. For this 
purpose two sets of schemes are delivered at each patient visit. 
Fig. 1 shows a flow chart of HISREG and a selection of variables.
The registry is supervised by a steering committee of clini-
cians and authors of this paper (GI, DND, KS, GBEJ, DM and 
LE). The committee decides which projects are licensed to use 
the database for peer-reviewed publishing. No single member 
of the committee can publish data without the consent of the 
committee and the contributors as a whole. 
The information and communication technology (ICT) 
used for data capture is a web-based solution in OpenQReg© 
(Geeknet, Fairfax, VA, USA). A separate reporting module is 
developed as part of the ICT solution, OpenQreg©, whereby the 
individual department will be given access to reports concerning 
their own patients. This solution will also provide clinics with 
access to data-sets for their own patients, and make it possible 
to download and process them at the individual clinics. The 
servers are based in Tromsø, Norway. 
Initially, the registry will be used by Departments of Der-
matology in 3 Scandinavian countries, Norway (Tromsø and 
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Fig. 1. HISREG (Clinical Scandinavian Registry for Hidradenitis Suppurativa) 
flow chart and variables.
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Trondheim), Denmark (Roskilde) and Sweden (Stockholm). 
More clinics may be added subsequently, and other areas of 
medicine, including plastic surgery and gynaecology, will be 
represented. The aim is to establish HISREG as a permanent 
quality registry in all 3 countries. One of the objectives of 
HISREG is to enable the sharing and comparison of data with 
other similar HS registries in other countries. To our know-
ledge, there is currently no such single registry in existence. 
Moreover, through the use of unique Scandinavian personal 
identification numbers, it will be possible to cross-link HISREG 
to other population-based registries, i.e. cancer registries, hos-
pital discharge patient registries, national databases for acute 
myocardial infarction, and cause-of-death registries. 
DISCUSSION
The creation of a Nordic HS registry will result in 
multiple benefits for this under-served disease. It will 
enable the analysis of different patient subpopulations 
and provide data for case-control studies and prospec-
tive cohort studies. 
The data obtained from HISREG may serve as a re-
source for quality control of treatment and patient care 
by clinicians and other healthcare providers, scientists, 
and others, by providing them with input regarding HS 
in Scandinavia. It is important for healthcare systems 
regularly to complete meaningful quality controls in 
order to review their activities. 
A registry answers several questions concerning the 
phenotype of patients, together with questions concer-
ning co-morbidities and medication. By analysing the 
registry database, one can determine which treatment is 
likely to have the greatest effectiveness and the lowest 
risk of side-effects for a given patient.
Over time, regulatory agencies and pharmaceutical 
companies have used spontaneous reporting to signal 
adverse drug reactions in the post-marketing set-
ting. However, this approach is not always sufficient. 
Registries, on the other hand, have the capability to 
compensate for some of the limitations of spontaneous 
reporting. This is especially relevant for unexpected 
side-effects.
The most effective design for a new registry is web-
based. However, the registry will be successful in the 
long run only if clinicians are willing to use it in daily 
practice. This will not be achieved merely through the 
simple understanding that every patient included in the 
registry is a step towards improved treatment for HS. 
A registry must also offer practical incentives: helping 
physicians to manage patients in everyday care and 
supporting their communication with patients. For 
 example, a useful tool is a summary that can be printed 
out for the patient at the end of a visit, presenting the 
current medication and a record of the course of the 
disease to date. 
There are few published, randomized, controlled trials 
of the best treatment for patients with HS (8). Controlled 
trials are therefore needed to compare the effects of dif-
ferent medical treatment modalities. Systemic compa-
rative studies are also required for surgical techniques, 
including evaluations of post-operative procedures, 
which are best performed as prospective cohort studies 
and thus would be eminently suited for HISREG.
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